US2010063088A1PendingUtilityA1

Raf Kinase Inhibitors

67
Individually held — no corporate assignee on recordPriority: May 23, 1997Filed: Nov 17, 2009Published: Mar 11, 2010
Est. expiryMay 23, 2017(expired)· nominal 20-yr term from priority
Inventors:Jill WoodHanno WildDaniel RogersJohn Francis LyonsMichael KatzYolanda CaringalRobert DallyWendy LeeRoger SmithCheri Blum
A61P 35/00C07D 409/12C07D 417/12C07D 207/34C07D 471/04C07D 333/38C07D 307/68
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       2 . A method according to  claim 1 , comprising administering a compound of the formulae 
     
       
         
         
             
             
         
       
     
   
   
       3 . A method according to  claim 1 , comprising administering a compound of the formulae 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       4 . A method according to  claim 1 , comprising administering a compound of formulae 
     
       
         
         
             
             
         
       
     
   
   
       5 . A method according to  claim 1 , comprising administering a compound of formulae 
     
       
         
         
             
             
         
       
     
   
   
       6 . A method according to  claim 1 , comprising administering a compound of formulae 
     
       
         
         
             
             
         
       
     
   
   
       7 . A method according to  claim 1 , comprising administering a compound of formulae 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       8 . A compound of the formulae 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       9 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
     
   
   
       10 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       11 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
     
   
   
       12 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
     
   
   
       13 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
     
   
   
       14 . A compound according to  claim 8 , of the formulae 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
   
   
       15 . A pharmaceutical composition comprising a compound according to  claim 8  and a physiologically acceptable carrier. 
   
   
       16 . A pharmaceutical composition comprising a compound according to  claim 14  and a physiologically acceptable carrier. 
   
   
       17 . A pharmaceutical composition comprising a compound according to  claim 8  and a physiologically acceptable carrier, in sterile form.

Join the waitlist — get patent alerts

Track US2010063088A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.